WallStreetZenWallStreetZen

NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock Ownership - Who owns Ars Pharmaceuticals?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Ars Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Eric KarasChief Commercial Officer2026-06-1225,000$1.50
$37.50kBuy
Alexander A. FitzpatrickChief Legal Officer2026-06-123,355$10.00
$33.55kSell
Eric KarasChief Commercial Officer2026-06-1225,000$10.00
$250.00kSell
Brian DorseyChief Operating Officer2025-11-1321,828$0.64
$13.97kBuy
Brian DorseyChief Operating Officer2025-11-1321,828$8.71
$190.06kSell
Justin ChakmaChief Business Officer2025-11-12136,380$8.86
$1.21MSell
Justin ChakmaChief Business Officer2025-11-1230,000$0.84
$25.20kBuy
Justin ChakmaChief Business Officer2025-11-1230,000$8.91
$267.36kSell
Kathleen D. ScottChief Financial Officer2025-08-2112,500$1.50
$18.75kBuy
Richard E. LowenthalPRESIDENT AND CEO2025-08-2150,000$14.49
$724.35kSell

1 of 2

SPRY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SPRY insiders and whales buy or sell their stock.

SPRY Shareholders

What type of owners hold Ars Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Richard E. Lowenthal22.11%21,952,529$211.84MInsider
Sarina Tanimoto20.50%20,360,336$196.48MInsider
Peter A. Thompson17.15%17,029,398$164.33MInsider
Orbimed Advisors LLC17.15%17,029,398$164.33MInsider
Ra Capital Management LP10.94%10,860,977$104.81MInstitution
James E. Flynn9.84%9,774,508$94.32MInsider
Orbimed Advisors LLC8.35%8,288,510$79.98MInstitution
Rubric Capital Management LP8.06%8,000,000$77.20MInstitution
Deerfield Management Company LP7.56%7,503,812$72.41MInstitution
Millennium Management LLC6.02%5,982,919$57.74MInstitution

1 of 3

SPRY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SPRY47.21%52.79%Net SellingNet Selling
SPTX0.00%74.81%Net BuyingNet Buying
XNCR72.61%27.39%Net SellingNet Selling
CGEM57.24%42.76%Net BuyingNet Selling
DBVT7.15%11.37%Net Selling
View Top Biotech Stocks

Ars Pharmaceuticals Stock Ownership FAQ

Who owns Ars Pharmaceuticals?

Ars Pharmaceuticals (NASDAQ: SPRY) is owned by 94.19% institutional shareholders, 105.33% Ars Pharmaceuticals insiders, and 0.00% retail investors. Richard E. Lowenthal is the largest individual Ars Pharmaceuticals shareholder, owning 21.95M shares representing 22.11% of the company. Richard E. Lowenthal's Ars Pharmaceuticals shares are currently valued at $211.84M.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.